From their web-site: We now intend to study BIOD-123 in a Phase 2 clinical trial that we expect to begin in the third calendar quarter of 2012.

If successful, it is conceivable that it could be approved in a few years. Even if this is after Afrezza, it would make it harder for Afrezza to ramp up to its potential market share.